Drug intelligence / Profile preview

AVN-0189

Development stage: Preclinical
Lead developer: Avineuro Pharmaceuticals
Modality: Small Molecules

Overview

AVN-0189 is a preclinical small molecule G protein-coupled receptor (GPCR) modulator being developed by Avineuro Pharmaceuticals in collaboration with ChemDiv. The compound is part of a research program focused on therapeutics for neurological disorders and central nervous system (CNS) diseases. While specific biological targets and indications have not been fully disclosed, the drug is categorized as a small molecule modulator within the GPCR class and remains in the early stages of development.

Beyond the preview

Go deeper on AVN-0189.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVN-0189.

Explore the full profile